[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"market-brand-preview-france":3,"market-product-preview-france":25,"related-news---France":30},{"data":4,"market":5,"productCount":21,"indexableProductCount":21,"pagination":22},[],{"verifiedAt":6,"indexable":7,"slug":8,"name":9,"iso2":10,"region":11,"accessModels":12,"status":14,"summary":15,"purchaseRule":16,"regulator":17,"sourceLabel":18,"sourceUrl":19,"sourceNote":20},"2026-08-27",true,"france","France","FR","Europe",[13],"medical_limited","Restricted transitional medical access","France has a cannabis-medicine framework in its Public Health Code and a tightly restricted transition route for patients from the national medical cannabis experiment while the permanent system is completed.","There is no general enrolment or adult-use market. Access is limited to the authorized medical pathway and eligible patients under the current transition rules.","Ministry of Health, ANSM, and Haute Autorité de Santé","French Ministry of Health — medical cannabis framework","https:\u002F\u002Fsante.gouv.fr\u002Factualites\u002Fpresse\u002Fcommuniques-de-presse\u002Farticle\u002Fnotification-des-textes-encadrant-l-usage-du-cannabis-medical-a-la-commission?lang=en","France has enacted a cannabis-medicine authorization framework; effective patient access remains restricted during the transition from the national experiment.",0,{"page":23,"limit":24,"total":21,"totalPages":23},1,6,{"data":26,"market":27,"pagination":29},[],{"verifiedAt":6,"indexable":7,"slug":8,"name":9,"iso2":10,"region":11,"accessModels":28,"status":14,"summary":15,"purchaseRule":16,"regulator":17,"sourceLabel":18,"sourceUrl":19,"sourceNote":20},[13],{"page":23,"limit":24,"total":21,"totalPages":23},{"data":31,"pagination":32},[],{"page":23,"limit":33,"total":21,"pages":23},3]